13:07 , Jan 17, 2019 |  BC Innovations  |  Emerging Company Profile

Zelluna’s solid TCR plans

Zelluna Immunotherapy A/S is using a portfolio of HLA class II-restrictive TCRs to develop autologous cell therapies that could unleash a broader immune attack on solid tumors than other TCR-based cell therapies in development. CEO...
14:01 , Jan 3, 2019 |  BC Innovations  |  Translation in Brief

Neo opportunities in glioblastoma

Phase I results from a consortium led by BioNTech AG and Immatics Biotechnologies GmbH convinced both companies that personalized immunotherapies can turn on T cell activity in glioblastoma, an immunologically "cold" cancer. The study is...
13:42 , Jan 3, 2019 |  BC Innovations  |  Distillery Techniques

Assays and screens; other

TECHNOLOGY: Cellular assays; computational models A computational method to predict HLA peptide presentation could help identify neoantigens for cancer immunotherapy. The deep learning model was trained on a data set to identify the relationships between...
04:20 , Dec 21, 2018 |  BC Innovations  |  Product R&D

Cell therapies seek solid ground

To make cell therapies work in solid tumors, drug companies will have to either master combination therapies or figure out how to make their treatments trigger broad immune responses that extend beyond the antigen specificity...
07:01 , Dec 18, 2018 |  BC Extra  |  Tools & Techniques

Gritstone showcases mass spec-based neoantigen discovery platform

Gritstone Oncology Inc. (NASDAQ:GRTS) unveiled the inner workings of its mass spectrometry-based neoantigen identification platform, EDGE, in a Nature Biotechnology study published Monday. Results from the paper suggest building a machine-learning algorithm based on human...
13:29 , Dec 5, 2018 |  BC Innovations  |  Distillery Techniques

Disease models

TECHNOLOGY: 3-D models Patient-derived placenta-like organoids could be used to study preeclampsia and other pregnancy-related disorders and screen therapies to treat them. The organoids are generated by culturing human placenta-derived trophoblasts in culture media with...
23:00 , Nov 12, 2018 |  BC Extra  |  Preclinical News

Sequencing-based method identifies neoantigen-specific TCRs

In a Nature Biotechnology paper , researchers described a method to identify TCRs that bind to specific neoantigens, which could enable efficient and inexpensive production of personalized T cell therapies. The high-throughput technique, developed by...
00:36 , Oct 19, 2018 |  BC Innovations  |  Tools & Techniques

Allogeneic CARs on the horizon

With the first generation of autologous, personalized CAR T cell therapies on the market, the field is turning to allogeneic technologies to provide better scale and lower costs. But drug makers are learning that as...
18:19 , Oct 18, 2018 |  BC Innovations  |  Distillery Techniques

Assays and screens; biomarkers

TECHNOLOGY: Cellular assays, diagnostic assays; plasma markers Circulating CD4 + T cells specific for full-length C-peptide could be used for early diagnosis of Type I diabetes. In peripheral blood samples from patients with recent-onset Type...
22:23 , Oct 11, 2018 |  BC Innovations  |  Translation in Brief

Cancer antigens from RNA edits

A team from Immatics Biotechnologies GmbH and University of Texas MD Anderson Cancer Center has shown that cancer antigens generated via post-transcriptional RNA editing could further broaden the target space for immunotherapies. The study ,...